Colitis, Ulcerative Clinical Trial
Official title:
Multicenter Non-Therapeutic Study of Infliximab for Severe Refractory Colitis in Hospitalized Children
This multicenter study is being conducted to determine whether infliximab exposure after an initial infusion is predictive of early clinical response in hospitalized pediatric patients with severe steroid-refractory UC or IBD-U. This pilot and feasibility study will establish the infrastructure, demonstrate feasibility, and collect preliminary data to support the full study.
This is a multicenter prospective non-interventional cohort study to identify clinical and
biological markers that predict non-response in hospitalized pediatric patients with severe
corticosteroid-refractory UC or inflammatory bowel disease unspecified (IBD-U) being
initiated on infliximab.
Patients hospitalized with severe UC or IBD-U (PUCAI ≥ 65 on admission) and failing
intravenous corticosteroids will be eligible. Blood, stool, and rectal biopsies (if
sigmoidoscopy performed for clinical indications) will be collected for translational studies
(Aim 3). Patients will receive infliximab per the dose and regimen determined by clinical
physician. No standard dosing regimen will be used and the dose of IFX will be determined by
the treating physician. Serial PUCAI scores and infliximab levels will be obtained.
Those who are eligible to participate will have serial blood samples taken in association
with drug infusions to perform pharmacokinetic/pharmacodynamic modeling of infliximab
exposure. Clinical response will be determined using the Pediatric UC Activity Index (PUCAI)
questionnaire.
Initially, 6 centers will participate with a minimum target enrollment goal of 36 evaluable
pediatric research participants (to a maximum of 40) age > 4 years or < 18 years old with UC
or IBD-U (average 6/center).
The primary endpoint will be the relationship between IFX exposure (area under the curve of
the PK model) and Day 7 clinical response defined as Pediatric Ulcerative Colitis Activity
Index (PUCAI) ≤ 35. Secondary endpoints will be Week 8 clinical remission, and Week 26
steroid-free, colectomy-free remission. We will initially enlist 6 centers, and enroll 36-40
evaluable patients in 2 years.
This study described by this protocol is designed as pilot and feasibility study, which we
anticipate will ultimately be expanded to larger study. Therefore, to demonstrate feasibility
and begin the development of a biorepository on this patient population, certain biospecimens
will be collected for this study and anticipated future translational studies as follows:
- Blood will be used for IFX pharmacokinetic assays (e.g. levels, antibodies) and future
biomarker discovery.
- Blood DNA we anticipate will be used for genotype/phenotype correlations and genetic
predictors of rapid infliximab clearance and non-response.
- Colon tissue RNA will be used for determining how local gene expression patterns predict
or explain infliximab clearance or non-response.
- Colon tissue DNA we anticipate will be used for studies of how the microbiome or
epigenetic changes relate to severe UC or response to infliximab.
- Colon tissue will be used for determining the relationship between tissue TNF levels (or
other proteins) and infliximab clearance or non-response.
- Stool will be collected for serial measurement of fecal calprotectin and future
microbiome studies
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04989907 -
A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
|
||
Completed |
NCT03494764 -
Hyperbaric Oxygen Therapy for Ulcerative Colitis Flares
|
Phase 2 | |
Recruiting |
NCT03937609 -
TITRATE (inducTIon for acuTe ulceRATivE Colitis)
|
Phase 4 | |
Completed |
NCT00503243 -
Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03606499 -
Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
|
||
Completed |
NCT02537210 -
Aminosalicylic Acid Withdrawal Study in Long Standing Inactive Ulcerative Colitis
|
N/A | |
Active, not recruiting |
NCT02316678 -
Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics
|
N/A | |
Completed |
NCT00488631 -
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT00928681 -
A Study To Investigate The Safety And Efficacy Properties Of PF-00547659 In Patients With Active Ulcerative Colitis
|
Phase 1 | |
Recruiting |
NCT05242484 -
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT01036022 -
Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis
|
Phase 2 | |
Recruiting |
NCT03841045 -
Unraveling a Potential Connection Between Bilirubin Metabolism, Gut Microbiota and Inflammatory Bowel Diseases
|
||
Active, not recruiting |
NCT05528510 -
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT02825914 -
CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM)
|
N/A | |
Recruiting |
NCT06049017 -
A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT04567628 -
Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical Outcomes
|
||
Withdrawn |
NCT05999708 -
A First Time in Human Study to Evaluate the Safety and Tolerability of GSK4381406 in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT05611671 -
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
|
Phase 2 | |
Active, not recruiting |
NCT03596645 -
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03648541 -
BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis
|
Phase 2 |